Category Archives: Multaq
Lawsuits over DePuy ASR Metal-on-Metal Hip Implants Continue to Mount
DePuy Orthopaedics and its parent, Johnson & Johnson, continue to be hit with lawsuits over recalled metal-on-metal DePuy ASR hip implants. Just yesterday, the national law firm of Parker Waichman LLP announced it had filed yet another DePuy ASR hip implant lawsuit, this time on behalf of a Virginia resident ...
1,000+ Australians Join DePuy ASR Hip Implant Class Action Lawsuit
A class action lawsuit filed in Australia over DePuy Orthopaedics’ recalled metal-on-metal ASR Hip Implants has signed up more than 1,000 plaintiffs. The attorneys representing the Australian ASR Hip Implant lawsuit plaintiffs recently told The Courier-Mail that damages in the lawsuit are expected to be worth more than $200 million. One ...
Tennessee Resident Files Pradaxa Bleeding Lawsuit Following Cerebral Hemorrhage
A man from Tennessee has filed a lawsuit against the maker of Pradaxa, claiming that the blood thinner caused him to suffer a cerebral hemorrhage. The complaint alleges Boehringer Ingelheim Pharmaceuticals, Inc. concealed knowledge that Pradaxa can cause Serious, life-threatening bleeds, and did not warn that Pradaxa bleeding side effects ...
Actos Whistleblower Lawsuit Questions Avandia Researcher's Financial Ties to Takeda
A prominent researcher has been implicated in an alleged cover-up of Actos side effects, according to a report from TheHeart.org. An Actos whistleblower lawsuit unsealed earlier this year has alleged financial connections between the Cleveland Clinic’s Dr Steven Nissen and the maker of Actos “should be considered when analyzing Actos’s ...
Pradaxa Associated with more Complications than Warfarin, According to Early Study Findings
Early results from the largest study to date to compare Pradaxa and warfarin indicate that in a real-world setting, Pradaxa causes more complications than decades-old warfarin. The preliminary study results were announced last week, during the 2012 Thrombosis and Hemostasis Summit of North America.
Fracking Should be Kept 600m From Aquifers, Study Says
New research on the safety of hydraulic fracturing (fracking) suggests new wells should not be dug within 600 meters of a water aquifer because underground fractures can extend about that far from a dug well. According to a report from UK’s The Guardian newspaper, researchers and geologists at Durham University have ...
First Bard Avaulta Transvaginal Mesh Lawsuit Scheduled for February Trial in MDL
The first test trials in the federal C.R. Bard Avaulta transvaginal mesh litigation will most likely start next year, according to a report from Bloomberg News. About 600 lawsuits involving Bard Avaulta transvaginal mesh products are currently pending in the multidistrict litigation underway Charleston, West Virginia. U.S. District Judge Joseph ...
National Law Firms Calls for More FDA Action on Actos Bladder Cancer Threat
A national law firm is not satisfied with the way the U.S. Food & Drug Administration (FDA) has handled warnings regarding Actos (pioglitazone) bladder cancer risks. In a statement published today, Parker Waichman LLP called on the FDA to compel Takeda Pharmaceuticals, the maker of the type 2 diabetes drug, ...
Bisphosphonate Study Confirms Atypical Thigh Fracture Risk
New research has confirmed the link between bisphoshonates, such as Fosamax, and atypical femur fractures, a type of thigh fracture that occurs spontaneously, without any major leg injury. The study, published in the Archives of Internal Medicine, also found that the risk of atypical thigh fractures increases the longer a ...
Multaq Patients Had Double Death Risk in Halted Trial
A study has found that patients taking < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq to control serious, permanent atrial fibrillation, may face a doubled risk of death. Such Multaq patients also face a much higher risk of suffering a heart attack and stroke, according to … Continue reading
Multaq Side Effect Concerns Prompt Restrictions in Europe
Use of < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq, the Sanofi-Aventis heart drug that has been linked to heart, liver and lung problems, has been restricted by regulators in Europe. According to a report from The Wall Street Journal, a committee of the European Medicines … Continue reading
Multaq Faces FDA Scrutiny As Safety Concerns Mount
The U.S. Food & Drug Administration (FDA) said yesterday that it is continuing to review the safety of < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq, as more and more specialists report they are no longer prescribing the drug. Multaq has been linked to a number … Continue reading
Multaq Maker Issues Formal Alert for Halted Study
Sanofi-Aventis has formally alerted doctors that a clinical trial involving < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone) was halted because patients in the study’s Multaq group were dying at more than twice the rate of that of patients taking placebo. “Healthcare professionals are advised … Continue reading
Canada Reviewing Multaq Over Heart Worries
Add Canada to the list of countries taking a deeper look into prescription medication, < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone). Health Canada, said CTV News, is reviewing the drug’s safety. Multaq is already approved to treat temporary Atrial Fibrillation (AF), or abnormal heart … Continue reading
New Multaq Alert Issued by FDA
Following an expanded European Medicines Agency (EMA) probe, the U.S. Food and Drug Administration (FDA), as expected, announced that it will be reviewing information from a < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq clinical trial that was stopped over higher-than-expected adverse heart reactions in trial … Continue reading
Multaq Heart Side Effects Under Review in Europe
Sanofi is facing an expansion of an ongoing review of its atrial fibrillation (AF) treatment, < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone). The European Medicines Agency (EMA) found that a study revealed possible heart risks in patients using the drug, said FiercePharma. The Agency … Continue reading
Multaq Trial Halted Due to Significant Increase in Heart Problems
A clinical trial for < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone) has ended early after a significant number of heart-related side effects were seen in the study. The trial, known as the PALLAS study, was testing Multaq’s as a treatment for permanent atrial fibrillation. … Continue reading
Multaq Patients Should Undergo Liver Function Tests
European regulators recently warned that < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (donedarone) could put patients at risk for severe liver injuries. The European Medicines Agency (EMA) is now recommending that doctors perform liver function tests before treating atrial fibrillation patients with Multaq. The European … Continue reading
Multaq Faces Liver Injury Review in Europe
< "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone), a drug used to treat atrial fibrillation made by Sanofi-Aventis, is being reviewed by European regulators for a possible connection to liver damage. Earlier this month, the U.S. Food & Drug Administration (FDA) announced that the label … Continue reading
